These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 26432092)

  • 21. A Narrative Review of Irritable Bowel Syndrome with Diarrhea: A Primer for Primary Care Providers.
    Moshiree B; Heidelbaugh JJ; Sayuk GS
    Adv Ther; 2022 Sep; 39(9):4003-4020. PubMed ID: 35869354
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Review article: an analysis of safety profiles of treatments for diarrhoea-predominant irritable bowel syndrome.
    Lacy BE
    Aliment Pharmacol Ther; 2018 Oct; 48(8):817-830. PubMed ID: 30194692
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of Irritable Bowel Syndrome.
    Spiller RC
    Curr Treat Options Gastroenterol; 2003 Aug; 6(4):329-337. PubMed ID: 12846942
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Modern Management of Irritable Bowel Syndrome: More Than Motility.
    Tack J; Vanuytsel T; Corsetti M
    Dig Dis; 2016; 34(5):566-73. PubMed ID: 27331917
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Double-Blind Placebo-Controlled Study of Rifaximin and Lactulose Hydrogen Breath Test in Gulf War Veterans with Irritable Bowel Syndrome.
    Tuteja AK; Talley NJ; Stoddard GJ; Verne GN
    Dig Dis Sci; 2019 Mar; 64(3):838-845. PubMed ID: 30370492
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Repeat Treatment With Rifaximin Is Safe and Effective in Patients With Diarrhea-Predominant Irritable Bowel Syndrome.
    Lembo A; Pimentel M; Rao SS; Schoenfeld P; Cash B; Weinstock LB; Paterson C; Bortey E; Forbes WP
    Gastroenterology; 2016 Dec; 151(6):1113-1121. PubMed ID: 27528177
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Eluxadoline in irritable bowel syndrome with diarrhea: rationale, evidence and place in therapy.
    Barshop K; Staller K
    Ther Adv Chronic Dis; 2017 Nov; 8(11):153-160. PubMed ID: 29090081
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rifaximin therapy for patients with irritable bowel syndrome without constipation.
    Pimentel M; Lembo A; Chey WD; Zakko S; Ringel Y; Yu J; Mareya SM; Shaw AL; Bortey E; Forbes WP;
    N Engl J Med; 2011 Jan; 364(1):22-32. PubMed ID: 21208106
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Eluxadoline for Irritable Bowel Syndrome with Diarrhea.
    Lembo AJ; Lacy BE; Zuckerman MJ; Schey R; Dove LS; Andrae DA; Davenport JM; McIntyre G; Lopez R; Turner L; Covington PS
    N Engl J Med; 2016 Jan; 374(3):242-53. PubMed ID: 26789872
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Diarrhea-Predominant Irritable Bowel Syndrome: Medical Management Update.
    Andrews CN; Bradette M
    J Can Assoc Gastroenterol; 2020 Dec; 3(6):e37-e48. PubMed ID: 33241185
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Eluxadoline Demonstrates a Lack of Abuse Potential in Phase 2 and 3 Studies of Patients With Irritable Bowel Syndrome With Diarrhea.
    Fant RV; Henningfield JE; Cash BD; Dove LS; Covington PS
    Clin Gastroenterol Hepatol; 2017 Jul; 15(7):1021-1029.e6. PubMed ID: 28167156
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacologic and complementary and alternative medicine therapies for irritable bowel syndrome.
    Chey WD; Maneerattaporn M; Saad R
    Gut Liver; 2011 Sep; 5(3):253-66. PubMed ID: 21927652
    [TBL] [Abstract][Full Text] [Related]  

  • 33. AGA Clinical Practice Guideline on the Pharmacological Management of Irritable Bowel Syndrome With Diarrhea.
    Lembo A; Sultan S; Chang L; Heidelbaugh JJ; Smalley W; Verne GN
    Gastroenterology; 2022 Jul; 163(1):137-151. PubMed ID: 35738725
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of irritable bowel syndrome.
    Trinkley KE; Nahata MC
    J Clin Pharm Ther; 2011 Jun; 36(3):275-82. PubMed ID: 21545610
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Review Article: Current and future treatment approaches for IBS with diarrhoea (IBS-D) and IBS mixed pattern (IBS-M).
    Nee J; Lembo A
    Aliment Pharmacol Ther; 2021 Dec; 54 Suppl 1():S63-S74. PubMed ID: 34927757
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacological Therapies and Their Clinical Targets in Irritable Bowel Syndrome With Diarrhea.
    Colomier E; Algera J; Melchior C
    Front Pharmacol; 2020; 11():629026. PubMed ID: 33679391
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety of Eluxadoline in Patients with Irritable Bowel Syndrome with Diarrhea.
    Cash BD; Lacy BE; Schoenfeld PS; Dove LS; Covington PS
    Am J Gastroenterol; 2017 Feb; 112(2):365-374. PubMed ID: 27922029
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Drugs for Irritable Bowel Syndrome.
    Med Lett Drugs Ther; 2020 Mar; 62(1594):25-32. PubMed ID: 32324172
    [No Abstract]   [Full Text] [Related]  

  • 39. Efficacy and Safety of Eluxadoline in Patients With Irritable Bowel Syndrome With Diarrhea Who Report Inadequate Symptom Control With Loperamide: RELIEF Phase 4 Study.
    Brenner DM; Sayuk GS; Gutman CR; Jo E; Elmes SJR; Liu LWC; Cash BD
    Am J Gastroenterol; 2019 Sep; 114(9):1502-1511. PubMed ID: 31356229
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evidence-based management of irritable bowel syndrome with diarrhea.
    Pimentel M
    Am J Manag Care; 2018 Jan; 24(3 Suppl):S35-S46. PubMed ID: 29372991
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.